Shirley D'Sa

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors
    Lara Groeneveldt
    Cancer Institute, University College London, 72 Huntley Street, WC1E 6DD, London, UK
    BMC Cancer 13:31. 2013
  2. ncbi request reprint T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, UK
    Br J Haematol 123:309-22. 2003
  3. ncbi request reprint Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, London, UK
    Br J Haematol 125:756-65. 2004
  4. ncbi request reprint Guidelines for the use of imaging in the management of myeloma
    Shirley D'Sa
    Department of Haematology, University College Hospital, London, UK
    Br J Haematol 137:49-63. 2007
  5. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
  6. doi request reprint Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma
    Neil Rabin
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 158:499-505. 2012
  7. ncbi request reprint Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
    Kirit M Ardeshna
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 130:363-72. 2005
  8. doi request reprint Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
    Sally Moore
    Department of Haematology, University College London Hospital UCLH, London, UK
    Eur J Haematol 90:420-5. 2013
  9. ncbi request reprint Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
    Charalampia Kyriakou
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 129:763-70. 2005
  10. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003

Collaborators

Detail Information

Publications11

  1. pmc A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors
    Lara Groeneveldt
    Cancer Institute, University College London, 72 Huntley Street, WC1E 6DD, London, UK
    BMC Cancer 13:31. 2013
    ....
  2. ncbi request reprint T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, UK
    Br J Haematol 123:309-22. 2003
    ..Over 80% of all patients have relapsed at a median of 283 (range 153-895) d after transplant, suggesting that the initially low rate of GVHD comes at a high price with regard to the desired graft-versus-myeloma effect...
  3. ncbi request reprint Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, London, UK
    Br J Haematol 125:756-65. 2004
    ..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
  4. ncbi request reprint Guidelines for the use of imaging in the management of myeloma
    Shirley D'Sa
    Department of Haematology, University College Hospital, London, UK
    Br J Haematol 137:49-63. 2007
    ..These stand-alone imaging guidelines discuss recommendations for the use of each modality of imaging at diagnosis and in the follow up of patients with myeloma...
  5. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  6. doi request reprint Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma
    Neil Rabin
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 158:499-505. 2012
    ..We conclude that CTD consolidation may be a useful, non-toxic and cost-effective strategy to deepen disease response following ASCT, and deserves further study in a randomized trial...
  7. ncbi request reprint Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
    Kirit M Ardeshna
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 130:363-72. 2005
    ..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
  8. doi request reprint Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
    Sally Moore
    Department of Haematology, University College London Hospital UCLH, London, UK
    Eur J Haematol 90:420-5. 2013
    ..Here, we report our experience of weekly intravenous bortezomib in clinical practice in relapsed/refractory patients...
  9. ncbi request reprint Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
    Charalampia Kyriakou
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 129:763-70. 2005
    ..We conclude that the CDT regimen is safe, well tolerated and effective in patients with relapsed and refractory myeloma...
  10. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003
    ..The novel and objective diversity scoring system described appears better able to document changes in spectratype patterns than previously described techniques and should aid the standardization of reporting...
  11. doi request reprint Guidelines for supportive care in multiple myeloma 2011
    John A Snowden
    Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
    Br J Haematol 154:76-103. 2011
    ..These guidelines should be read in conjunction with the BCSH/UKMF Guidelines for the Diagnosis and Management of Multiple Myeloma 2011...